Indoco Aims For Growth Despite Inconsistent Indian Pharma Market
Company Counts On Its COVID-19 Related Products To Perform
Failing to see the predicted recovery in the Indian pharma market, Indoco has re-evaluated its expectations, acknowledging that it may have to wait longer to see a return to pre-COVID domestic sales figures. The Indian company’s managing director, Aditi Panandikar, talks to Generics Bulletin about Indoco’s plans amidst inconsistent market trends.
You may also be interested in...
India’s Indoco has reported double-digit growth despite a slow recovery of its domestic business during its financial third quarter ended 31 December 2020. The Indian company reported 18% sales growth overall, lifted by 73% growth in its International business in Q3.
Indoco’s domestic performance picks up pace as the Indian pharma market sees a “bounce back” after a long COVID-induced slump. The Indian company continues to perform well internationally and grow overall.
The Advancing Education on Biosimilars Act and the Ensuring Innovation Act will be looked at by the US President Joe Biden, after receiving the approval of both the Senate and the House of Representatives. The bills are aimed at lowering prescription drug costs and saving overall healthcare costs.